In May 2022, The US FDA authorized the use of RADICAVA ORS (edaravone) in an oral formulation for the treatment of ALS.
This has been a recurring theme in the past 12 months. During a news conference at Mar-a-Lago on 7 January 2025, he floated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback